- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02691962
Xen Matrix™ AB Surgical Graft in Ventral or Incisional Midline Hernias
September 24, 2021 updated by: C. R. Bard
A Post-Market, Prospective, Multicenter, Single-Arm Trial of XenMatrix™ AB Surgical Graft in All Wound Classes Ventral or Incisional Midline Hernias
This study aims to prospectively explore the use of XenMatrix™ AB Surgical Graft for ventral or incisional midline hernia repair in patients across all wound classes ("All Comers") through 24 months post repair.
Study Overview
Detailed Description
This is a post-market, on-label study to understand the performance of the graft in the US.
Study Type
Interventional
Enrollment (Actual)
75
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- Keck Hospital of USC
-
San Francisco, California, United States, 94107
- California Pacific Medical Center - Sutter Health
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Missouri
-
Saint Louis, Missouri, United States, 63108
- Washington University
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Trustees of the University of Pennsylvania
-
-
Texas
-
El Paso, Texas, United States, 79430
- Texas Tech University Health Sciences Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject must be willing and able to give written informed consent.
- Subject must be diagnosed with a ventral or incisional midline hernia.
- Mesh must be placed in the retro-rectus or intraperitoneal plane.
- Subject must be willing to undergo open hernia repair and be able to undergo all other study procedures as outlined in this protocol.
Exclusion Criteria:
- The use of surgical graft as a bridge repair.
- The subject has more than 4 prior recurrences.
- Subject has a contraindication for the placement of surgical graft.
- Complete removal of existing mesh from a prior hernia repair (in the same affected area) is not possible.
- The study hernia repair requires more than a single piece mesh (including sufficient overlap beyond margins of the defect on all sides).
- Subject has intact permanent mesh adjacent to the current hernia to be repaired.
- Subject has peritonitis at the time of surgery.
- The subject is an active smoker within the last 2 weeks prior to surgery.
- Clinically significant Chronic Obstructive Pulmonary Disease or heart failure, defined as marked limitation in ability or inability to perform activities of daily living.
- Subject had chemotherapy within the last 12 months, is on or suspected to be placed on chemotherapy medications during any part of the study.
- Chronic steroid use (>6 months) or immunosuppression drugs.
- Subject's body mass index (BMI) >45 kg/m2.
- Subject has cirrhosis, and/or ascites.
- Subject has a defined collagen disorder.
- Known to be infected with human immunodeficiency virus (HIV).
- Subject has clinically significant (not based solely on creatinine levels) kidney disease that limits Activities of Daily Living, is on hemodialysis or peritoneal dialysis.
- Subject is American Society of Anesthesiology (ASA) Class 4 or 5.
- Subject has a life expectancy < 2 years at the time of enrollment.
- Subject is pregnant, breastfeeding or planning on becoming pregnant during the course of the study.
- Subjects with known sensitivity to porcine products.
- Subjects with allergy, history of allergy or hypersensitivity to tetracyclines (including minocycline) or rifamycins (including rifampin).
- Subject has any condition in the opinion of the Investigator that would preclude the use of the study device, or preclude the subject from completing the follow-up requirements.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Xen Matrix AB
Subjects treated with Xen Matrix AB
|
Xen Matrix™ AB Surgical Graft is an acellular, sterile, non-pyrogenic porcine dermal matrix packed dry for use in the reconstruction of soft tissue deficiencies.
The device surfaces are coated with the antibacterial agents Rifampin and Minocycline in a bioresorbable L-Tyrosine succinate polymer carrier.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Wound Occurrences Up to 45 Days Post Implantation
Time Frame: Up to 45 days post implantation
|
Wound occurrences were defined as surgical site infection, seroma, wound dehiscence, skin necrosis and fistulas requiring intervention.
|
Up to 45 days post implantation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Wound Occurrences > 45 Days Post Implantation
Time Frame: Day 45 and up to 2 years post implantation
|
Wound occurrences was defined as surgical site infection, seroma, wound dehiscence, skin necrosis and fistulas requiring intervention.
|
Day 45 and up to 2 years post implantation
|
Number of Participants With Hernia Recurrence Within 6 Months and 24 Months of Implantation Procedure
Time Frame: Within 6 months and 24 months of implantation procedure
|
Within 6 months and 24 months of implantation procedure
|
|
Number of Participants With Reoperation Due to Index Hernia Repair
Time Frame: 24 months post implantation procedure
|
24 months post implantation procedure
|
|
Total Score on the Carolinas Comfort Scale (CCS) at Baseline, 1, 3, 6, 12, 18, and 24 Months Post Implantation Procedure
Time Frame: Baseline, 1, 3, 6, 12, 18, and 24 months post implantation procedure
|
The Carolinas Comfort Scale (CCS) quality of life questionnaire aimed for patients who have had hernia repair surgery.
Symptoms in the CCS are rated by the participants on a scale of 0 to 5, with a score of 0 suggesting no symptoms and a score of 5, disabling symptoms.
A lower score on the questionnaire compared to baseline would indicate a better outcome.
|
Baseline, 1, 3, 6, 12, 18, and 24 months post implantation procedure
|
General Health Score on the Short Form 12 (SF-12) Questionnaire at Baseline, 1, 3, 6, 12, 18, and 24 Months Post Implantation.
Time Frame: Baseline, 1, 3, 6, 12, 18, and 24 months post implantation
|
The Short Form 12 (SF-12) is a self-reported 12-item questionnaire that evaluates general health and well-being (overall quality of life of an individual).
The SF-12 includes questions on physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health.
Scores range from 0 to 100, with higher scores indicating better levels of functioning.
|
Baseline, 1, 3, 6, 12, 18, and 24 months post implantation
|
Number of Participants Who Returned to Work Post Implantation Procedure
Time Frame: Up to 2 years following implantation procedure
|
Up to 2 years following implantation procedure
|
|
Duration of Participants Stay in Hospital Following Implantation Procedure
Time Frame: From index procedure day to discharge from hospital day
|
From index procedure day to discharge from hospital day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Robert Martindale, MD, Oregon Health and Science University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2016
Primary Completion (Actual)
May 1, 2020
Study Completion (Actual)
May 1, 2020
Study Registration Dates
First Submitted
February 22, 2016
First Submitted That Met QC Criteria
February 22, 2016
First Posted (Estimate)
February 25, 2016
Study Record Updates
Last Update Posted (Actual)
October 21, 2021
Last Update Submitted That Met QC Criteria
September 24, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DVL-HE-012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Incisional Hernia
-
W.L.Gore & AssociatesRecruitingHernia, Ventral | Hernia Incisional | Hernia Incisional VentralUnited States, Spain, Italy, United Kingdom
-
Zagazig UniversityCompletedIncisional Hernia of Midline of Abdomen | Incisional Hernia of Midline of Upper Abdomen | Incisional Hernia of Midline of Lower AbdomenEgypt
-
Mansoura UniversityUnknownHernia, Abdominal | Hernia, Ventral | Hernia IncisionalEgypt
-
C. R. BardCompletedHernia | Hernia, Abdominal | Hernia, IncisionalBelgium, Netherlands, Denmark, France, Italy, United Kingdom, Austria, Germany
-
Hospital Central "Dr. Ignacio Morones Prieto"UnknownHernia, Ventral | Ventral Incisional Hernia
-
Universitaire Ziekenhuizen KU LeuvenBelgian Section for Abdominal Wall Surgery, section of the Royal Belgian...Not yet recruitingVentral Incisional Hernia
-
University of PennsylvaniaCompleted
-
Medtronic - MITGCompletedVentral Incisional HerniaFrance
-
Azienda Sanitaria Locale Napoli 2 NordCompletedHernia, Abdominal | Hernia IncisionalItaly
-
Hospital Regional de Alta Especialidad del BajioCompleted
Clinical Trials on Xen Matrix AB
-
AqueSys, Inc.CompletedPrimary Open Angle GlaucomaSpain, Austria, Belgium, Italy, Germany, Poland, Switzerland, United Kingdom, Venezuela
-
Xention LtdCompletedAtrial FibrillationUnited Kingdom
-
Price Vision GroupTerminated
-
Xention LtdArio Pharma LtdCompletedChronic Idiopathic CoughUnited Kingdom, Ireland
-
Johns Hopkins UniversityNew York UniversityCompletedGlaucoma, Open-AngleUnited States
-
Washington University School of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedRoux-en-Y Gastric Bypass | Bariatric Surgery | Vertical Sleeve Gastrectomy | Gastric Banding | Bypass, GastricUnited States
-
Pila PharmaCompletedDiabetes Mellitus, Type 2Denmark
-
Swiss Vision NetworkActive, not recruitingGlaucoma | Glaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Primary Open Angle
-
Mingche Biotechnology CO., LTDNot yet recruiting
-
AllerganCompletedRefractory GlaucomaChina